- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03071042
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Hongming Pan, MD
- Phone Number: +86-13605716662
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Recruiting
- Sir Run Run Shaw Hospital
-
Contact:
- Pan Hongming, MD
- Phone Number: +86-13605716662
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
- Age: ≥18 years old;
Locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma ) patients confirmed by radiologic imaging or endoscopy tests, who had failed in first-line treatments;
- First-line treatment should be 5-Fu combined with platinum based regimen;
- Adjuvant/neoadjuvant chemotherapy should be defined as the first-line treatment, if recurrence happened within 6 months after completion of 5-Fu and platinum based adjuvant/ neoadjuvant chemotherapy;
- Adjuvant/neoadjuvant chemotherapy history is allowed, if first-line treatment is applied more than 6 months later than prior treatments;
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure;
- ECOG Performance Status ≤1;
- Life expectancy shouldn't less than 16 weeks, since the first medicine application time;
Major organ function has to meet the following criteria (within 28 days before treatment):
- HB ≥9.0 g/dL
- ANC ≥1.5X109/L
- PLT ≥100x109/L
- Bilirubin ≤1.5 times the upper limit of normal (ULN)
- ALT (SGOT) and AST (SGPT) ≤2.5 × ULN, unless liver metastases; if any, the ALT and AST≤5 × ULN
- Serum Cr ≤ 1.5 x ULN
- Patients must have at least one assessable lesion (including measurable and/or immeasurable) by radiological imagine (CT/MRI);
Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 28 days before enrollment and the test result must be negative. Or menopause women, defined as follow:
- ≥1 year no menstruation, after abort exogenous hormone treatment
- Serum LH and FSH meet menopause criteria
- More than 1 year no menstruation for ovarian function failure induced by radiation therapy.
- More than 1 year no menstruation for menopause induced by chemotherapy
- Surgical sterilization accepted (hysterectomy or ovariectomy)
Exclusion Criteria:
- Involved in another on-going clinical trials;
- Accept more than one chemotherapy previously in advanced gastric cancer (except more than 6 months from adjuvant/neoadjuvant treatment);
- Prior taxane treatment (including Paclitaxel and Docetaxel);
- Prior VEGFR inhibitor treatment (including Sorafenib and Sunitinib);
- History of another malignancy within the last five years except cured nonmelanoma Skin cancer and carcinoma in situ of uterine cervix;
- Any factors that influence the usage of oral administration;
- History of the investigational agent treatment in 14 day prior to enroll in study (longer time period may be required which depends on drug characteristic);
- Accept any chemotherapy and radiotherapy (excluding Palliative radiotherapy) in 3 weeks prior to study (longer time period may be required which depends on drug characteristic);
- Poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class I; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class I cardiac dysfunction; Patients with positive urinary protein;
- Poor-controlled adverse events (excluding Alopecia) induced by tumor therapy (>class 1 CTCAE);
- History of intestinal obstruction or more than class 3 or 4 (CTCAE) gastrointestinal bleeding in 4 weeks prior to enroll in study;
- Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;
- Clinical evidence in central nervous system (CNS) and poor-controlled CNS metastasis (No necessary to confirm negative CNS metastasis by CT/MRI);
- Surgery within 2 weeks prior to enroll in study;
- History of significant and poor-controlled diseases or infection, in the opinion of investigators, may impact the safety of the patients of the study;
- Known history of human immunodeficiency, e.g. HIV positive;
- Known or suspected allergy to the investigational agent or any agent given in association with this trial;
- Pregnant or lactating patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apatinib plus Docetaxel
Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed.
If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively.
This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
|
Apatinib Mesylate Tablets 425mg (500mg,675mg or 750mg) po.
qd continuous;
Other Names:
Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tolerance profile of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: At least 4 weeks
|
At least 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Hongming Pan, MD, The Affiliated Sir Run Run Shaw Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ahead-G306
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Gastric Adenocarcinoma
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
Astellas Pharma Global Development, Inc.AvailableMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma CancerUnited States
-
Hospices Civils de LyonRecruitingGastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic AdenocarcinomaFrance
-
University of Southern CaliforniaNational Cancer Institute (NCI); IpsenWithdrawnGastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma | Metastatic Unresectable Gastric AdenocarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityNot yet recruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction AdenocarcinomaChina
-
Zhou FuxiangHubei Cancer Hospital; Henan Provincial People's Hospital; Huangshi Central Hospital...RecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction AdenocarcinomaChina
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
China Medical University, ChinaGeneral Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaboratorsUnknownMetastatic Gastric AdenocarcinomaChina
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Clinical Trials on Apatinib
-
Elevar TherapeuticsCompletedAdenoid Cystic CarcinomaUnited States, Korea, Republic of
-
Shanghai Jiao Tong University Affiliated Sixth...UnknownSoft Tissue Sarcoma
-
Tianjin Medical University Cancer Institute and...Unknown
-
Lei LiCompletedChemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 InhibitorChina
-
Peking University Cancer Hospital & InstituteRecruiting
-
Huazhong University of Science and TechnologyUnknown
-
Wuhan Union Hospital, ChinaWithdrawnColorectal Cancer | Chemotherapy | Angiogenesis
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.Unknown
-
Ruijin HospitalActive, not recruitingGastric and Gastroesophageal Junction (GEJ) AdenocarcinomaChina